47 results
8-K
EX-10.1
4mubcv53j8cx45grw
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
D
st1 tvx648
19 Feb 21
$10.24M in equity / options, sold $10.24M, 18 investors
9:26am
8-K
EX-99.1
8cle c61ate
5 Nov 20
Processa Pharmaceuticals Announces the Appointment of
9:00am
8-K
EX-1.1
rsq92 q1c4bqrdn
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
424B4
svzlf tf8
5 Oct 20
Prospectus supplement with pricing info
4:16pm
8-K
EX-10.1
s0j5jkkp2630r
27 Aug 20
Entry into a Material Definitive Agreement
9:30am